RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at $44.94, the stock has ...

In 2025, the AI landscape is undergoing a transformative shift, expanding into two critical new layers: the application layer ...

USA News Group News Commentary ? As the new administration starts to make its mark in the United States, President Trump recently announced a $500 billion AI infrastructure investment in the country, ...